MCD – Fundamental snapshot (Sep 2026)
VALUATION: $171B mkt cap. P/E 19.6x TTM, 18.7x fwd, EV/EBITDA 15x, FCF yield ~4.5%, dividend yield 3.1% (payout ~60%). Well below the mid-20s multiples of recent years – a big de-rating is already priced.
QUALITY INTACT: operating margin ~46%, net margin ~32%, FCF $7.8B (28% margin), ROIC ~17%. ~95% franchised = asset-light, royalty-like cash flows. Beta 0.3.
GROWTH IS THE ISSUE: Q2 global comps only +1.3% (US +0.8%), revenue +4%, EPS +6% (TTM EPS $12.31).
INVESTOR DAY (Sep 23): $8.5B franchisee support through 2036 (~$5B by 2030) via rent relief + capital. Targets for 2030: op. margin low-to-mid 50%, FCF conversion mid-to-high 80%; ~$3B/yr baseline capex 2027-30. No EPS target → market prices the near-term margin/FCF drag while the payoff is years away.
BALANCE SHEET: net debt ~$54B (~3.6x EBITDA), negative equity from buybacks. Normal for a stable franchisor, but rent relief could slow buybacks.
CATALYST: Q3 results Oct 22 (consensus EPS ~$3.39). Watch US comps, first sizing of NEXT costs in 2027 guidance, buyback pace.
BOTTOM LINE: a quality compounder at a sub-20 P/E, but the discount reflects real uncertainty – weak comps plus a decade-long reinvestment cycle. The value case needs comps to re-accelerate.
Not investment advice.
VALUATION: $171B mkt cap. P/E 19.6x TTM, 18.7x fwd, EV/EBITDA 15x, FCF yield ~4.5%, dividend yield 3.1% (payout ~60%). Well below the mid-20s multiples of recent years – a big de-rating is already priced.
QUALITY INTACT: operating margin ~46%, net margin ~32%, FCF $7.8B (28% margin), ROIC ~17%. ~95% franchised = asset-light, royalty-like cash flows. Beta 0.3.
GROWTH IS THE ISSUE: Q2 global comps only +1.3% (US +0.8%), revenue +4%, EPS +6% (TTM EPS $12.31).
INVESTOR DAY (Sep 23): $8.5B franchisee support through 2036 (~$5B by 2030) via rent relief + capital. Targets for 2030: op. margin low-to-mid 50%, FCF conversion mid-to-high 80%; ~$3B/yr baseline capex 2027-30. No EPS target → market prices the near-term margin/FCF drag while the payoff is years away.
BALANCE SHEET: net debt ~$54B (~3.6x EBITDA), negative equity from buybacks. Normal for a stable franchisor, but rent relief could slow buybacks.
CATALYST: Q3 results Oct 22 (consensus EPS ~$3.39). Watch US comps, first sizing of NEXT costs in 2027 guidance, buyback pace.
BOTTOM LINE: a quality compounder at a sub-20 P/E, but the discount reflects real uncertainty – weak comps plus a decade-long reinvestment cycle. The value case needs comps to re-accelerate.
Not investment advice.
Haftungsausschluss
Die Informationen und Veröffentlichungen sind nicht als Finanz-, Anlage-, Handels- oder andere Arten von Ratschlägen oder Empfehlungen gedacht, die von TradingView bereitgestellt oder gebilligt werden, und stellen diese nicht dar. Lesen Sie mehr in den Nutzungsbedingungen.
Haftungsausschluss
Die Informationen und Veröffentlichungen sind nicht als Finanz-, Anlage-, Handels- oder andere Arten von Ratschlägen oder Empfehlungen gedacht, die von TradingView bereitgestellt oder gebilligt werden, und stellen diese nicht dar. Lesen Sie mehr in den Nutzungsbedingungen.